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High-grade urothelial carcinoma with squamous
differentiation metastasizing to the tongue
Q4 Syed A. Khurram, BDS, MSc, PhD, MFDS RCS (Ed),a Paula M. Farthing,a Abigail Whitworth,b
Alasdair McKechnie,c and Malee FernandodQ1
Tumors metastasizing to the head and neck region are uncommon. Metastasis of urothelial carcinoma to the
maxillofacial region is exceedingly rare and mostly involves the jaw. We present a case of urothelial carcinoma metastasizing
to the tongue. Immunohistochemistry in conjunction with fluorescent in situ hybridization was used to confirm the relation
between the primary and metastatic lesions, making it the first such reported case employing the UroVysion (Catalogue
number 02 J27-025, Abbott Molecular Inc., Des Plaines, IL, USA) fluorescent in situ hybridization probe in a metastatic lesion
in the head and neck region. (Oral Surg Oral Med Oral Pathol Oral Radiol 2015;-:e1-e5)
Primary tumors from distant sites metastasizing to the
head and neck region are rare and involve the maxil-
lofacial bones (i.e., mandible and maxilla), soft tissues,
or, rarely, the mucosa. Carcinomas arising in the lung,
breast, and kidney show the highest tendency for oral
metastases.1-3 Oral and maxillofacial metastases from
bladder urothelial carcinoma (UC) are exceedingly rare,
making the diagnosis challenging. Most of the reported
metastases involve the jaw, with only two metastases to
the tongue reported. We present a case of tongue
metastasis from a UC showing prominent squamous
differentiation with cytokeratin 7 (CK7) and CK20
negativity. Fluorescent in situ hybridization (FISH)
with UroVysion probes (Catalogue number 02 J27-025,
Abbott Molecular Inc., Des Plaines, IL, USA) was used
to confirm the relation between primary and metastatic
UC. This is the first reported case using FISH to
identify metastatic UC and should be considered in
metastatic tumors in the head and neck region with an
unknown origin.
CASE REPORT
A 90-year-old male was referred by his general practitioner to
the local oral and maxillofacial surgery clinic with a 3-week
history of pain involving the left lower jaw. The patient
complained of severe pain involving his left lower face and
difficulty swallowing and eating. As a result, he had suffered
significant weight loss and was restricted to a soft mashed
diet. The patient had a previous history of chronic stage 3
kidney disease and heart failure and was on a range of related
medications. The patient was a nonsmoker and only occa-
sionally consumed alcohol. He also had a history of high-
grade UC with invasion of the muscularis propria, which
had been diagnosed a year earlier and for which he had
declined treatment.
The patient had been referred to the Urology department
with hematuria 12 months before the oral symptoms man-
ifested. Endoscopic examination showed a solid lesion
involving the right side of the bladder wall, and the patient
underwent computed tomographic urography, blood in-
vestigations, and a transurethral biopsy. Hematologic in-
vestigations showed low mean cell hemoglobin concentration
at 315 g/L (normal 335-370) and raised eosinophils at 0.58 
109/L (normal 0.04-0.5). Urea and electrolytes showed raised
urea 9.9 mmol/L (normal 2.5-7.8) and raised total bilirubin at
25 mmol/L (normal 0-21). Histologic examination of the
bladder biopsies confirmed a focally plasmacytoid UC (grade
3 WHO 1973; high-grade WHO 2004/ISUP) with invasion of
the muscularis propria but without vascular invasion. The
patient was deemed unfit for surgery following a multidisci-
plinary team discussion. Radical radiotherapy was considered
because the tumor appeared treatable, however; this was
declined by the patient, who decided against any treatment
interventions and wished to be treated expectantly.
Approximately a year later, the patient presented with oral
symptoms and was found to have a large (6-cm), palpable,
erythematous lesion involving the left side of the tongue
(Figure 1A). The tongue appeared fixed, with reduced mobility,
and there was a suggestion of mandibular bone involvement.
There was no obvious infiltration into the pharynx, and
occasional small cervical lymph nodes were palpable in level
I on the left. The clinical impression was that of an oral
squamous cell carcinoma, and metastatic UC was included in
the provisional diagnosis because of the clinical history.
An orthopantomogram was obtained and did not reveal any
significant findings. Magnetic resonance imaging showed a
large mass measuring 6.5 cm anteroposteriorly, involving the
entire left tongue and extending across the midline
(Figure 1B). Involvement of the extrinsic tongue muscles and
the floor of mouth and mandibular bone invasion were
evident. There was no extension into the lateral wall of the
pharynx or the parapharyngeal fat. The level I lymph nodes
on the left appeared reactive.
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An incisional biopsy of the tongue mass was performed.
Histologic examination of hematoxylin and eosin sections
showed mucosal fragments widely infiltrated by islands of
malignant cells with focal squamous differentiation. Tumor
islands showed nuclear and cellular pleomorphism, prominent
nucleoli, focal areas of keratinization, and a high mitotic rate.
The overlying surface epithelium did not exhibit dysplasia,
and the origin was not evident from the overlying epithelium
in the biopsy (Figure 2). The surrounding stroma had a poor
host response.
Immunohistochemistry was performed for CK5/6, CK7,
CK20, thrombomodulin, Ki67, GATA3, and uroplakin III to
establish the origin of the infiltrative tumor cells. Tumor
islands showed strong expression of CK5 and CK6 and
thrombomodulin, with no expression of CK7, CK20, GATA3,
or uroplakin III (Figure 3). Ki67 showed a proliferation index
greater than 30% (not shown).
Due to the lack of CK7 and CK20 expression, FISH
analysis was performed on the bladder and tongue specimens
by using the UroVysion Bladder Cancer Kit (Abbott Molec-
ular Inc.) to determine the association between the two. The
UroVysion multiprobe FISH kit (Abbott Molecular Inc.) was
developed to overcome the diagnostic limitations of urinary
cytology.4 Probes for chromosomes 3, 7, and 17 are included
because polysomies of these are quite frequent in bladder
cancer. The 9p21 region is the site of the tumor suppressor
gene p16, with its deletion being a frequent and early event
in UC development. Recent studies have shown that it can
be used with similar accuracy between fresh and formalin-
fixed paraffin-embedded (FFPE) tissue.5
FISH was performed on FFPE tissue sections, as described
previously.5 Analysis of 100 interphase nuclei in FFPE
sections from both specimens showed evidence of
aneuploidy for chromosomes 3, 7, and 17, in addition to
loss of p16 on chromosome 9. The FISH findings for the
tongue deposit were identical to those of the original
bladder lesion. Given that specific FISH probes were chosen
Fig. 1. A, Clinical examination showed a nodular, firm, and
erythematous swelling involving the left tongue. The smaller
nodular lesion seen on the buccal aspect of the edentulous
mandibular alveolar ridge was consistent with denture-related
fibrous hyperplasia. B, Magnetic resonance imaging (coronal
view, T2 weighted) showing a large, ill-defined lesion
involving the left tongue and crossing the midline.
Fig. 2. A, Hematoxylin and eosin section of oral specimen
with infiltrative tumor showing focal squamous differentia-
tion. No obvious origin from the overlying epithelium was
evident. A high-resolution version of this slide for use with the
Virtual Microscope is available as eSlide: VM00743. B,
Infiltrative primary urothelial carcinoma (UC) from the same
patient (10 original magnification).
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from 10 different candidate loci because they demonstrated
the highest combined sensitivity for detecting UC, this was
interpreted as confirming the urothelial origin for the tongue
metastasis (Figure 4).
DISCUSSION
Malignant tumors metastasizing to the oral cavity or
maxillofacial region are rare and are most commonly
those with a tendency for bone metastases (such as
breast, lung, kidney, thyroid, and prostate carcinomas).
However, there are numerous reported cases of these
being presentations of undiscovered malignancies.6
Trends of metastasis to the oral cavity also do not
reflect the incidence, biologic behavior, and aggres-
siveness of the primary tumor. For example, lung car-
cinoma is one of the most common cancers with oral
metastasis in males and is followed by carcinomas of
the kidney, liver, and prostate, which show a much
lower incidence. In contrast, prostate carcinoma is the
most common malignancy in males, followed by lung,
colorectal, and bladder cancers.6,7 Furthermore, some
highly aggressive tumors, such as pancreatic cancer,
rarely metastasize to the oral cavity.
UC represents 90% of bladder malignancies and
usually presents in the sixth or seventh decade of life,
with a male predilection (3:1 to 4:1).8 It is an aggressive
neoplasm, which can metastasize frequently and early,
but rarely to the head and neck region or the oral
cavity. Direct invasion and spread into structures
adjacent to the bladder is commonly seen, and
metastases usually involve the regional lymph nodes,
lung, liver, and lumbar and thoracic vertebrae.9-11
Fig. 3. Immunohistochemistry for the metastatic deposit. A,
Cytokeratin (CK) 5/6. A high-resolution version of this slide
for use with the Virtual Microscope is available as eSlide:
VM00739. B, Thrombomodulin. A high-resolution version of
this slide for use with the Virtual Microscope is available as
eSlide: VM00745. Strong staining for CK 5/6 and thrombo-
modulin was seen in the infiltrating tumor islands (10
original magnification). Staining for CK7, CK20, Uroplakin
III, and GATA3 was negative (not shown). CK7. A high-
resolution version of this slide for use with the Virtual
Microscope is available as eSlide: VM00740. CK20. A high-
resolution version of this slide for use with the Virtual Mi-
croscope is available as eSlide: VM00741. Uroplakin III. A
high-resolution version of this slide for use with the Virtual
Microscope is available as eSlide: VM00746. GATA3. A
high-resolution version of this slide for use with the Virtual
Microscope is available as eSlide: VM00742. Ki-67 showed a
high proliferation index. A high-resolution version of this
slide for use with the Virtual Microscope is available as
eSlide: VM00744.
Fig. 4. Fluorescent in situ hybridization (FISH) analysis of
the tongue deposit using the UroVysion Bladder Cancer Kit
(Catalogue number 02 J27-025, Abbott Molecular Inc., Des
Plaines, IL, USA). Tumor nuclei showed an increased copy
number (polysomy) of the chromosomes 3 (aqua, 4 signals), 7
(spectrum-red, 4-5 signals), but a normal copy number of
chromosome 17 (spectrum-green, 2 signals) and loss (dele-
tion) of 9p21 (spectrum-gold, 0-1 signals) (100 original
magnification). FISH was also performed on the primary
urothelial carcinoma, which exhibited an identical pattern to
that of the tongue mass (not shown).
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Both hematogenous involvement and lymphatic
involvement can result in wider tumor dissemination.
Metastases may also arise from tumor cells being
shunted into alternate vascular compartments in the
presence of occluded local lymph nodes through
intercommunication of the perivascular lymphatic and
vascular systems.9 Hematogenous spread of bladder
cancer can result from tumor infiltration into the
vesical or prostatic venous plexuses and bypass the
major caval system to cause distant metastasis
through the vertebral venous system.9
Metastasis of bladder carcinomas to the maxillofacial
region is quite rare, with only 18 published cases re-
ported in the literature, most of which involve the
maxilla or the mandible. There are three reports
involving the cheek, submental soft tissue, and the
submandibular gland (Table I8-24Q2 ). Metastasis of UC to
the tongue is exceeding rare, with only two cases re-
ported in the literature to date.11,24 Within the jaws, the
posterior mandible and maxilla distal to the canines are
usually involved.5 In most cases, the available treatment
options are palliative rather than curative, with
associated mortality within several months to 2
years.11,21
The immunophenotype was not typical, but UCs with
squamoid features are known to show positive reac-
tivity for CK5 and CK6. The absence of CK7 staining
by the metastatic tumor in the current case was
somewhat unusual, but CK7 expression in UC with
squamous differentiation has been reported to be vari-
able. These can exhibit strong CK5 and CK6 staining,
absence of CK20, thrombomodulin and uroplakin III
staining, and at times only focal CK7 positivity.25,26
Staining patterns in metastatic bladder lesions can
also vary from the primary lesion. A recent study
compared expression of these markers in metastatic UC
and suggested that uroplakin expression is lost but that
CK7 staining and thrombomodulin staining are seen in
92% and 80% of metastatic UCs, respectively.27
However, Only 28% of metastatic UCs showed CK20
staining in this study.
GATA3 expression has been shown as a promising
marker for primary UC and regional metastases.28
Expression of GATA3 has been reported in greater
than 70% of primary UCs and matched regional
metastases.29 This pattern is similar among
conventional, micropapillary, and plasmacytoid UCs,
with weak staining in sarcomatoid and small-cell vari-
ants. However, it is not known whether GATA3
expression is maintained in distant metastases.
FISH has been shown to be a reliable technique for
the detection of increased chromosome copy number
(polysomies), amplifications and deletions of DNA loci,
and translocations. It is now a standard method to
identify chromosomal aberrations in urine cytology
specimens with prognostic, screening, and predictive
utility.30-33 The UroVysion kit (Abbott Molecular Inc.)
comprises a mixture of four different DNA probes, each
with a different flourophore (three centromere probes
for chromosomes 3, 7, and 17 and a probe for the 9p21
locus).34 This, therefore, is designed to detect
aneuploidy for chromosomes 3, 7, 17, and loss of the
9p21 which are consistently expressed in UC.
The tumors in our study showed changes identical to
the changes reported in high-grade UC.
The Urovysion FISH probes (Abbott Molecular Inc.)
have been shown to be highly specific in diagnosing
UC with a higher sensitivity (86%) compared with
cytology (61%).35 However, FISH has significant
implications in relation to the cost of reagents,
availability of infrastructure, and expertise of analysis.
We recommend the use of FISH in metastatic bladder
lesions only in selected cases showing absence of
CK7, CK20, and GATA3 expression.
To our knowledge, the current case is the third re-
ported case of UC metastasizing to the tongue and the
first to employ FISH testing to establish the correlation
between the primary and metastatic tumors. The rarity
of these lesions can make diagnosis challenging, espe-
cially in cases with prominent squamous differentiation
and limited CK7 expression. Multimodality pathologic
testing helps refine the diagnosis, and our experience
suggests that the UroVysion probe kit (Abbott
Table I. Studies reported in the English language
literature, to date, on urothelial carcinoma metastasizing
to the maxillofacial/oral region
Serial no. Paper Site of metastasis
1 Koper et al., 197511 Tongue
2 Treggiden, 197612 ND
3 Dunnick and Anderson,
197913
Mandible
4 Edwab et al., 198110 Submandibular gland
5 Polastri, Giugiaro, and
Gerbino, 198614
ND
6 Weithmann, Morrison, and
Hurt, 198815
Mandible
7 Cohen et al., 19899 Right maxilla
8 Hirshberg et al., 199316 Mandible
9 Doval et al., 199417 Maxilla
10 Doval et al., 199417 Mandible
11 Cardona, Bagan, and Perez,
200018
Mandibular gingiva
12 De Courten et al., 20018 Right maxilla




14 Lee et al., 2012Q3 21 Right buccal vestibule
15 Qiu et al., 201322 Left mandible condyle
16 Kumar Goyal et al., 201323 Right cheek
17 Kaleva et al., 201524 Left tongue
ND, Not described.
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Molecular Inc.) offers a reliable method for identifying
such lesions and in establishing the urothelial origin.
Metastatic UC should be included in the differential
diagnosis of poorly differentiated lesions in the head
and neck region without obvious origin from the sur-
face epithelium and with limited or absent CK7
expression.
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